EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

(2019) Ivana Sestak et al.   BREAST CANCER RESEARCH AND TREATMENT

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

(2019) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance

(2019) Morgan Wang et al.   PATHOLOGY

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

(2019) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx

(2019) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

(2019) Frédérique Penault-Llorca et al.   BREAST

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2017) Ian Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2016) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis

(2015) Federico Augustovski et al.   BREAST CANCER RESEARCH AND TREATMENT

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

(2015) F Fitzal et al.   BRITISH JOURNAL OF CANCER

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

(2015) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009

(2015) Michaela A. Dinan et al.   JAMA Oncology

Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience

(2014) Xiaofu Zhu et al.   EUROPEAN JOURNAL OF CANCER

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

(2013) Josh J. Carlson et al.   BREAST CANCER RESEARCH AND TREATMENT

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

(2013) Berit Maria Müller et al.   PLoS One

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

(2012) P. Dubsky et al.   ANNALS OF ONCOLOGY

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY